The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Fox Chase researchers to use $497K NCI grant to develop platform for testing pancreatic cancer drug therapies

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Researchers at Fox Chase Cancer Center have received a $497,000 multi-year grant from NCI to develop a way to evaluate novel drug therapies in patients with pancreatic cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Immunity against CMV leveraged against pancreatic cancer in study by UCSD, La Jolla Institute of Immunology

Researchers at the University of California San Diego and La Jolla Institute of Immunology have discovered a promising treatment approach for pancreatic cancer, one of the deadliest and most treatment-resistant forms of cancer. The approach leverages the body’s natural immune response to cytomegalovirus, a common but typically harmless virus that most people are infected with at some point in their lives. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account